Skip to main content
IMS Events Main banner
Back

    Andrew Spencer, MBBS FRACP, FRCPA, DM

    Professor
    Alfred Health-Monash University
    Melbourne, Victoria, Australia

    Professor Andrew Spencer is Head of the Malignant Haematology, Transplantation and Cellular Therapy Service at The Alfred Hospital, Professor of Haematology at Monash University and Head of the Myeloma Research Group, all in Melbourne, Australia. Professor Spencer undertook his medical training in clinical and laboratory hematology at the Princess Alexandra Hospital, Brisbane, and the Royal Prince Alfred Hospital, Sydney. He was then awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, United Kingdom where he undertook research into B-cell clonality in chronic myeloid leukemia and was awarded a Doctorate in Medicine from the University of London. He moved The Alfred Hospital in 1999, was appointed Head of Malignant Haematology, Transplantation and Cellular Therapy Service in 2007 and established an early phase haematology clinical trials unit in 2009, with currently over 190 blood cancer trials open and >900 registered trial patients. He has >300 peer reviewed publications with over 28,000 citations and holds 5 international patents in multiple myeloma therapeutics. Since 2019 he has been an invited speaker at over 50 international meetings on genomics, therapeutics and disease monitoring in multiple myeloma and is an invited investigator of the International Myeloma Foundation (IMF) Black Swan Research Initiative. He serves as an advisor to the IMF and the International Myeloma Working Group. He Chairs the Myeloma and Related Diseases Registry (MRDR), the APAC MRDR and the associated M1000 liquid biopsy biobank. He established the Australasian Myeloma Research Consortium (AMaRC) in 2016.

    Disclosure information not submitted.

    Presentation(s):